Correlation Between C4 Therapeutics and Cellectis

Can any of the company-specific risk be diversified away by investing in both C4 Therapeutics and Cellectis at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining C4 Therapeutics and Cellectis into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between C4 Therapeutics and Cellectis SA, you can compare the effects of market volatilities on C4 Therapeutics and Cellectis and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in C4 Therapeutics with a short position of Cellectis. Check out your portfolio center. Please also check ongoing floating volatility patterns of C4 Therapeutics and Cellectis.

Diversification Opportunities for C4 Therapeutics and Cellectis

0.01

Correlation Coefficient

C4 Therapeutics  Cellectis

Significant diversification

The 3 months correlation between CCCC and Cellectis is 0.01. Overlapping area represents the amount of risk that can be diversified away by holding C4 Therapeutics and Cellectis SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Cellectis SA and C4 Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on C4 Therapeutics are associated (or correlated) with Cellectis. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Cellectis SA has no effect on the direction of C4 Therapeutics i.e., C4 Therapeutics and Cellectis go up and down completely randomly.

Pair Corralation between C4 Therapeutics and Cellectis

Given the investment horizon of 90 days C4 Therapeutics is expected to under-perform the Cellectis. But the stock apears to be less risky and, when comparing its historical volatility, C4 Therapeutics is 1.23 times less risky than Cellectis. The stock trades about -0.3 of its potential returns per unit of risk. The Cellectis SA is currently generating about 0.21 of returns per unit of risk over similar time horizon. If you would invest  316.00  in Cellectis SA on July 18, 2025 and sell it today you would earn a total of  95.00  from holding Cellectis SA or generate 30.06% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	95.65%
Values	Daily Returns

C4 Therapeutics  vs.  Cellectis SA

C4 Therapeutics

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in C4 Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak fundamental indicators, C4 Therapeutics may actually be approaching a critical reversion point that can send shares even higher in November 2025.

Cellectis SA

Risk-Adjusted Performance

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Cellectis SA are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak essential indicators, Cellectis unveiled solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with C4 Therapeutics and Cellectis

The main advantage of trading using opposite C4 Therapeutics and Cellectis positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if C4 Therapeutics position performs unexpectedly, Cellectis can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cellectis will offset losses from the drop in Cellectis' long position.

The idea behind C4 Therapeutics and Cellectis SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.